Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31510376 | 0.86 | GRM5 (0.50) | GRM5LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1306384 | 0.84 | GABRA1 (0.38) | GRM5LMNAMAPTALDH1A1CYP1A2 | |
| SCHEMBL1306505 | 0.81 | APP (0.41) | GRM5LMNAMAPTALDH1A1CYP1A2 | |
| SCHEMBL1820120 | 0.78 | HDAC8 (0.58) | GRM5HDAC8FFAR1DDAH1NOS1 | |
| SCHEMBL563613 | 0.77 | APP (0.55) | GRM5MTORLMNAMAPTALDH1A1 | |
| SCHEMBL2854252 | 0.77 | CYP1A1 (0.44) | GRM5CYP1A2 | |
| Methyl Alcohol SCHEMBL28280712 | 0.76 | GRM5 (0.52) | GRM5HDAC8FFAR1PIK3CAMTOR | |
| SCHEMBL1649302 | 0.75 | HDAC8 (0.55) | GRM5HDAC8FFAR1PIK3CAMTOR | |
| Diphenylacetylene SCHEMBL3842452 | 0.75 | APP (0.60) | GRM5FFAR1MTORLMNAMAPT | |
| SCHEMBL19174201 | 0.75 | CYP1A1 (0.48) | GRM5MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878849-A | Method for preparing higher-order cyclic type cable hydrocarbon supermolecular compound | 安徽工业大学 | 2024-11-01 | — | — | CN | claimed |
| CN-111416154-B | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2021-08-06 | — | — | CN | claimed |
| CN-111416154-A | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2020-07-14 | — | — | CN | claimed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| CN-118878849-A | Method for preparing higher-order cyclic type cable hydrocarbon supermolecular compound | 安徽工业大学 | 2024-11-01 | — | — | CN | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-11970499-B1 | Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-30 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501808-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | disclosed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003091227-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091226-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1319231-A1 | PROGRAMMABLE MOLECULAR DEVICE | Wm. MARSH RICE UNIVERSITY (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20030058697-A1 | Programmable molecular device | NAVY, SECRETARY OF THE, UNITED STATES OF AMERICA OFFICE OF NAVAL RESEARCH | 2003-03-27 | — | — | US | disclosed |
| WO-2002009117-A1 | PROGRAMMABLE MOLECULAR DEVICE | WM. MARSH RICE UNIVERSITY (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | GRM5 379/4885HDAC8 1793/4885FFAR1 3875/4885 |
| US-11970499-B1 | Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors | CDK2, TK1, CDK1 | GRM5 2729/4885HDAC8 2768/4885FFAR1 4200/4885 |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | GRM5 3287/4885HDAC8 915/4885FFAR1 2856/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | GRM5 4520/4885HDAC8 971/4885FFAR1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.